The role of IL-6 and IL-6 blockade in COVID-19
| Autor: | Antonella Cappelli, Ettore Porreca, Nicola Potere, Alberto Batticciotto, Aldo Bonaventura, Antonio Abbate, Alessandra Vecchié, Francesco Dentali |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
lymphocytes
medicine.medical_treatment Immunology Anti-Inflammatory Agents sarilumab Disease Bioinformatics Siltuximab chemistry.chemical_compound tocilizumab Tocilizumab Receptors medicine Immunology and Allergy Animals Humans Interleukin 6 COVID-19 IL-6 SARS-CoV-2 cytokine storm hyperinflammation pathophysiology prognosis siltuximab Host-Pathogen Interactions Interleukin-6 Receptors Interleukin-6 Signal Transduction Treatment Outcome biology business.industry medicine.disease Pathophysiology Blockade COVID-19 Drug Treatment Cytokine chemistry biology.protein Cytokine storm business |
| Zdroj: | Expert review of clinical immunology. 17(6) |
| ISSN: | 1744-8409 |
| Popis: | INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a dysregulated hyperinflammatory response. AREAS COVERED: Authors review evidence on IL-6 and IL-6 blockade in coronavirus disease 2019 (COVID-19) and discuss the pathophysiological and prognostic roles of this cytokine and the clinical impact of pharmacological blockade of IL-6 . The material includes original articles and reviews published from March 2020 to March 2021 and searched on PubMed, medRxiv, and bioRxiv. EXPERT OPINION: IL-6 is one of the most prominent pro-inflammatory cytokines. Increased levels are recorded in COVID-19 patients, especially those with severe-to-critical disease. Evidence is accumulating on the relevance of IL-6 as a prognostic marker in COVID-19. Since IL-6 is a druggable target for several inflammatory diseases, pharmacological blockers of the IL-6 signaling pathway were repurposed to blunt the abnormal SARS-CoV-2-induced cytokine release. Data are limited to few randomized controlled trials that reported encouraging, though not conclusive, results, indicating the usefulness of IL-6 blockade early in the course of the disease in patients with hyperinflammation and no or limited organ damage. Further research is warranted to explore the role of IL-6 in different COVID-19 phenotypes and identify subgroups of patients who may mostly benefit from IL-6 pathway inhibition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|